RECIPIENT License. In granting an Exclusive License to any Project Results, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereof) for education, research and other non-commercial purposes, and the right to grant the licenses pursuant to Section D2.02 below.
Appears in 9 contracts
Samples: Cancer Research Grant Contract (Molecular Templates, Inc.), Cancer Research Grant Contract (Plus Therapeutics, Inc.), Cancer Research Grant Contract (Medicenna Therapeutics Corp.)
RECIPIENT License. In granting an Exclusive License to any Project ResultsResult, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereof) for education, research and other non-commercial purposes, and the right to grant the licenses pursuant to Section D2.02 below.
Appears in 6 contracts
Samples: Cancer Research Grant Contract (Bellicum Pharmaceuticals, Inc), Cancer Research Grant Contract (ESSA Pharma Inc.), Cancer Research Grant Contract (ESSA Pharma Inc.)
RECIPIENT License. In granting an Exclusive License to any Project Results, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereofthereof [***]) for education, research and other non-commercial purposes, and the right to grant the licenses pursuant to Section D2.02 below.. (F) In Part 2, Section D2.02, delete this section in its entirety and replace with the following amended Section D2.02, as shown below: Section D2.02
Appears in 2 contracts
Samples: State of Texas (Molecular Templates, Inc.), Cancer Research Grant Contract (Molecular Templates, Inc.)
RECIPIENT License. In granting an Exclusive License to any Project Results, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereof) for education, research and other non-commercial purposes, and the right to grant the licenses pursuant to Section D2.02 below.. Section D2.02
Appears in 1 contract
Samples: www.sec.gov
